HippoFi
-
Regulatory
PUR Biologics Secures Innovative Medical Patent With Strong Financial Upside
IRVINE, CA., September 12, 2023 / OrthoSpineNews / – Solidifying its role as a leader in medical advancements, PUR Biologics,…
Read More » -
Biologics
HippoFi Announces Strategic Alliance to Lead Spinal Biologics Innovation
IRVINE, CA., September 6, 2023 / OrthoSpineNews / – HippoFi, Inc. (OTCPK: ORHB) proudly announces a partnership with global medical…
Read More » -
Biologics
HippoFi to Announce Strategic Alliance with Orthopedic Leader
IRVINE, CA., September 1, 2023 / OrthoSpineNews / – HippoFi, Inc. (OTCPK: ORHB) – HippoFi, in association with its wholly…
Read More » -
Biologics
HippoFi Finalizes an Exclusive Strategic Partnership with International Biomedical Manufacturing Company, BPB Medica
PUR Biologics, a HippoFi biotech company, launches PURmarrow360 with BPB Medica, aiming to improve US patient safety and clinical outcomes…
Read More » -
Biologics
HippoFi Anticipates a New Strategic Partnership as the Company Prepares to Launch PURmarrow 360, a Patented Stem Cell Harvesting Device
IRVINE, CA., July 25, 2023 /OrthoSpineNews/ – HippoFi, Inc. (OTCPK:ORHB) a leading healthcare technology company and authority in spinal biologics,…
Read More » -
Biologics
HippoFi is Finalizing Definitive Agreements to Join Forces with Industry Giant to Revolutionize the Spinal Biologic Market
IRVINE, CA., July 25, 2023 /OrthoSpineNews/ – HippoFi, Inc. (OTCPK:ORHB) – HippoFi, a healthcare technology and innovation firm focused on…
Read More » -
Biologics
HippoFi’s PUR Biologics Granted National Approval at the Veterans Health Administration (VHA), the Largest Integrated Healthcare System in the United States
The nation’s largest system includes 1,298 healthcare facilities IRVINE, CA., June 28, 2023 / OrthoSpineNews / – HippoFi, Inc. (OTCPK:ORHB)…
Read More » -
Biologics
PUR Biologics Begins Shipment of its Breakthrough Product PURbonedough™
PURbonedough™ positioned to capture its share of the forecasted total spine market expected to grow from 13.3 billon in 2023…
Read More » -
Biologics
PUR Biologics Expands Sales Network by 15% Adding 32 New Distributors
IRVINE, CA., April 27, 2023 /OrthoSpineNews/ – HippoFi, Inc. (OTCPK: ORHB), a leading healthcare innovator and technology company, is proud…
Read More » -
Biologics
Goldman Small Cap Research Publishes New Research Report on HippoFi, Inc.
BALTIMORE, MD., April 21, 2023 /OrthoSpineNews/ – Goldman Small Cap Research, a stock market research firm specializing in the small cap…
Read More » -
Biologics
HippoFi Announces Its Return to a Pink Current Information Tier on the OTC Market
IRVINE, CA., April 12, 2023 /OrthoSpineNews/ – HippoFi, Inc. (OTC Pink: ORHB), a diversified company focused on the biotech and…
Read More » -
Biologics
PUR Biologics Announces Launch of PURcore™, a bioActive Moldable Synthetic for Spine Surgery
IRVINE, CA., April 6, 2023 /OrthoSpineNews/ – PUR Biologics, a subsidiary of HippoFi, Inc. (OTC Pink: ORHB), is proud to…
Read More » -
Biologics
HippoFi Begins 2023 with Strong Sales of Advanced Biomaterials
Expanded sales force fuels market growth. IRVINE, CA., January 13, 2023 /OrthoSpineNews/ – HippoFi, Inc. (formerly ORHub), (OTC Pink: ORHB),…
Read More » -
Spine
HippoFi’s Regenerative Therapeutics Division Launches PURbridge™ for Spine Surgery
PURbridge™, an advanced synthetic and new form of bioactive glass, is positioned to significantly increase the Company’s revenue throughout 2023…
Read More » -
Biologics
HippoFi Signs Strategic Partnership Agreement With Precision Spine, Inc.
“HippoFi accesses Precision Spine’s major sales channels to speed its sales strategy & quickly drive revenue” IRVINE, CA, October 5, 2022,…
Read More »